Among immunosuppressants, the mammalian target of rapamycin (mTOR) inhibitors, sirolimus and everolimus, are strongly associated with an increase in triglycerides, VLDL, and LDL, because they inhibit LPL function; reduce catabolism of the apolipoproteins, ApoB100 and apoCIII; alter insulin secretion; and induce pancreatic β-cells apoptosis [67,68,69]; these alterations are probably responsible for the significantly higher incidence of cardiovascular disease shown in patients treated with mTOR inhibitors (ROR 1.95, 95% CI: 1.70–2.23) [70]. Here, MTOR is linked to cardiovascular disorder.